滚动资讯
FierceBiotechSanofi’s bispecific scores double respiratory phase 2 wins, but flunks eczema studyFierceBiotechBiogen links up with Alloy platform to boost ASO drug developmentEndpoints NewsBioNTech to shutter Singapore HQ after 'comprehensive review'Endpoints NewsSanofi bispecific sails through asthma, sinusitis trials, but disappoints in eczemaeLifeSeparating selection from mutation in antibody language modelseLifeRethinking how memories are retrievedThermo FisherHow Thermo Fisher’s Glacios 3 aims to broaden access to cryo-EM - R&D WorldThermo FisherLobbying Update: $21,000 of THERMO FISHER SCIENTIFIC INC lobbying was just disclosed - Quiver QuantitativeFierceBiotechTakeda tears up Denali partnership, returning dementia asset amid restructuringFierceBiotechAI model designs new treatment candidate for opioid addiction that cuts cravings in ratsAgilentAgilent CLO Departing With Severance After Less Than 2 Years in Role - Law.comBioPharma DiveHims & Hers says limited data stolen in social engineering attack
FierceBiotech 2026年4月7日

Sanofi’s bispecific scores double respiratory phase 2 wins, but flunks eczema study

Sanofi’s bispecific scores double respiratory phase 2 wins, but flunks eczema study

原文
暂时没有全文，请查看原始来源。

目录

59 全部